Continuous clinical remission with biologics in ulcerative colitis: the 'AURORA' comparison study.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
pubmed:
28
9
2022
medline:
3
11
2022
entrez:
27
9
2022
Statut:
ppublish
Résumé
Comparative trials among biological drugs for the treatment of ulcerative colitis (UC) provided conflicting results. After patent expire of infliximab originator, adalimumab, infliximab biosimilar, golimumab and vedolizumab have been approved in Italy.We compared the efficacy of these four biologics in UC according to the concept of continuous clinical remission (CCR). In a retrospective, multicentre study, all UC patients treated with adalimumab, infliximab biosimilar, golimumab or vedolizumab between 2014 and 2019 were included. All drugs were compared to each other according to the 1-year CCR rate, defined as Mayo partial score ≤2, with bleeding subscore = 0, without any relapse or optimization with dose escalation, topical treatments or steroid use after first clinical remission. Four-hundred sixteen patients (adalimumab = 90, infliximab biosimilar = 105, golimumab = 79, vedolizumab = 142) were included. CCR was achieved in similar percentages among the groups (33%, 37%, 28%, 37%, respectively). All drugs were equivalent in biologic-naive patients, while vedolizumab was better than a second anti-TNFα in prior anti-TNFα agent failures. No differences were found according to type of adverse events or severe adverse events. Based on a strict definition of clinical remission, all biologics appear equally effective at 1 year. Changing to vedolizumab is more effective than switching to another anti-TNFα in TNFα failures.
Identifiants
pubmed: 36165081
doi: 10.1097/MEG.0000000000002443
pii: 00042737-202212000-00006
doi:
Substances chimiques
Adalimumab
FYS6T7F842
Infliximab
B72HH48FLU
Biosimilar Pharmaceuticals
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1238-1246Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015; 110:1324–1338.
Ardizzone S, Cassinotti A, de Franchis R. Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opin Emerg Drugs. 2012; 17:449–467.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, et al.; VARSITY Study Group. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019; 381:1215–1226.
Gies N, Kroeker KI, Wong K, Fedorak RN. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther. 2010; 32:522–528.
Singh S, Heien HC, Sangaralingham LR, Schilz SR, Kappelman MD, Shah ND, Loftus EV. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis. Aliment Pharmacol Ther. 2016; 43:994–1003.
Sandborn WJ, Sakuraba A, Wang A, Macaulay D, Reichmann W, Wang S, et al. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin. 2016; 32:1233–1241.
Ananthakrishnan AN, Cagan A, Cai T, Gainer VS, Shaw SY, Savova G, et al. Comparative effectiveness of infliximab and adalimumab in Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2016; 22:880–885.
Renna S, Orlando E, Macaluso FS, Maida M, Affronti M, Giunta M, et al. Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis. Aliment Pharmacol Ther. 2016; 44:310–311.
Singh S, Andersen N, Andersson M, et al. Higher risk of hospitalization and serious infection among patients with ulcerative colitis treated with adalimumab, compared with infliximab, in a nationwide study. Clin Gastroenterol Hepatol. 2017; 15:1218–1225.
Mizoshita T, Katano T, Tanida S, Hirano A, Miyaki T, Ozeki K, et al. Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy. Medicine (Baltimore). 2017; 96:e7800.
Renna S, Mocciaro F, Ventimiglia M, Orlando R, Macaluso FS, Cappello M, et al. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. Dig Liver Dis. 2018; 50:1292–1298.
Allamneni C, Venkata K, Yun H, Xie F, DeLoach L, Malik TA. Comparative effectiveness of vedolizumab vs. infliximab induction therapy in ulcerative colitis: experience of a real-world cohort at a tertiary inflammatory bowel disease center. Gastroenterology Res. 2018; 11:41–45.
Di Domenicantonio R, Trotta F, Cascini S, Agabiti N, Kohn A, Gasbarrini A, et al. Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. Clin Epidemiol. 2018; 10:203–213.
Chen C, Hartzema AG, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O, et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis. 2019; 25:1417–1427.
Mshimesh B. Studying activity and toxicity of different TNF-alpha inhibitors in controlling patients with active ulcerative colitis. J Appl Pharmaceut Sci. 2019; 9:87–96.
Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, et al. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019; 49:873–879.
Favale A, Onali S, Caprioli F, Pugliese D, Armuzzi A, Macaluso FS, et al.; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Comparative efficacy of vedolizumab and adalimumab in ulcerative colitis patients previously treated with infliximab. Inflamm Bowel Dis. 2019; 25:1805–1812.
Davis R, McParland P, Dodd S, Storey D, Probert C, Collins P, et al. Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis. Eur J Gastroenterol Hepatol. 2019; 31:661–667.
Han M, Jung YS, Cheon JH, Park S. Comparison of real-world outcomes of infliximab versus adalimumab in biologic-naïve Korean patients with ulcerative colitis: a population-based study. Yonsei Med J. 2020; 61:48–55.
Gil-Candel M, Gascon-Canovas JJ, Urbieta-Sanz E, et al. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease. Int J Clin Pharm. 2020; 42:500–507.
Singh S, Proudfoot JA, Dulai PS, Xu R, Feagan BG, Sandborn WJ, Jairath V. Comparative efficacy and speed of onset of action of infliximab vs golimumab in ulcerative colitis. Clin Gastroenterol Hepatol. 2020; 18:424–431.e7.
Long MD, Smith TW, Dibonaventura M, Gruben D, Bargo D, Salese L, Quirk D. Real-world effectiveness of advanced therapies among patients with moderate to severe ulcerative colitis in the United States. Inflamm Bowel Dis. 2020; 26:941–948.
Hupé M, Rivière P, Nancey S, Roblin X, Altwegg R, Filippi J, et al. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. Aliment Pharmacol Ther. 2020; 51:852–860.
Barberio B, Zingone F, Frazzoni L, D’Incà R, Maccarone MC, Ghisa M, et al. Real-life comparison of different anti-TNF biologic therapies for ulcerative colitis treatment: a retrospective cohort study. Dig Dis. 2021; 39:16–24.
Hoque S, Puenpatom A, Boccaletti S, Green C, Black CM, Roberts J, et al. Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience. BMJ Open Gastroenterol. 2020; 7:e000476.
Loftus EV Jr, Sands BE, Colombel JF, Dotan I, Khalid JM, Tudor D, Geransar P. Sustained corticosteroid-free clinical remission during vedolizumab maintenance therapy in patients with ulcerative colitis on stable concomitant corticosteroids during induction therapy: a post hoc analysis of GEMINI 1. Clin Exp Gastroenterol. 2020; 13:211–220.
Macaluso FS, Ventimiglia M, Fries W, Viola A, Cappello M, Scrivo B, et al.; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis. Dig Liver Dis. 2020; 52:1461–1466.
Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, et al. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review. BMC Gastroenterol. 2020; 20:211.
Rundquist S, Sachs MC, Eriksson C, Olén O, Montgomery S, Halfvarson J; SWIBREG Study Group. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers. Aliment Pharmacol Ther. 2021; 53:471–483.
Lukin D, Faleck D, Xu R, Zhang Y, Weiss A, Aniwan S, et al. Comparative safety and effectiveness of vedolizumab to tumor necrosis factor antagonist therapy for ulcerative colitis. Clin Gastroenterol Hepatol. 2022; 20:126–135.
Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, et al. Vedolizumab and anti-tumour necrosis factor α real-world outcomes in biologic-naïve inflammatory bowel disease patients: results from the EVOLVE study. J Crohns Colitis. 2021; 15:1694–1706.
Shin JY, Park HM, Lee MY, Jeon JY, Yoo HJ, Ye BD. Real-world incidence of suboptimal response to anti-tumor necrosis factor therapy for ulcerative colitis: a nationwide population-based study. Gut Liver. 2021; 15:867–877.
Cassinotti A, Mezzina N, Massari A, et al. Head to head comparison of biological drugs in the treatment of ulcerative colitis: suggestions from a real life, inception cohort, single centre study on consecutive post-marketing treatments. J Crohns Colitis. 2018; 12(S1):S466.
Imai K, Ratkovic M. Covariate balancing propensity score. J Royal Statist Soc. 2014; Series B 76:243–263.
Travis SP, Higgins PD, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011; 34:113–124.
Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, et al. Heterogeneity in definitions of endpoints for clinical trials of ulcerative colitis: a systematic review for development of a core outcome set. Clin Gastroenterol Hepatol. 2018; 16:637–647.e13.
Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011; 60:780–787.
Peyrin-Biroulet L, Van Assche G, Armuzzi A, Garcia-Alvarez L, Lara N, Black CM, et al. Implementing the concept of continuous clinical response into clinical practice for ulcerative colitis. Clin Gastroenterol Hepatol. 2017; 15:1154–1161.e1.
Reinisch W, Colombel JF, Gibson PR, Rutgeerts P, Sandborn WJ, Tarabar D, et al. Continuous clinical response is associated with a change of disease course in patients with moderate to severe ulcerative colitis treated with golimumab. Inflamm Bowel Dis. 2019; 25:163–171.
Narula N, Alshahrani AA, Yuan Y, Reinisch W, Colombel JF. Patient-reported outcomes and endoscopic appearance of ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019; 17:411–418.e3.
Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011; 141:1194–1201.
Bianchi Porro G, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther. 2007; 26:779–794.
Cesarini M, Katsanos K, Papamichael K, Ellul P, Lakatos PL, Caprioli F, et al. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis. 2014; 46:135–139.
Taxonera C, Iborra M, Bosca-Watts MM, Rubio S, Nantes Ó, Higuera R, et al. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis. Curr Med Res Opin. 2019; 35:1297–1304.
Peyrin-Biroulet L, Danese S, Argollo M, Pouillon L, Peppas S, Gonzalez-Lorenzo M, et al. Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn's disease or ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019; 17:838–846.e2.
Taxonera C, Rodríguez C, Bertoletti F, Menchén L, Arribas J, Sierra M, et al.; Collaborators. Clinical outcomes of golimumab as first, second or third anti-TNF agent in patients with moderate-to-severe ulcerative colitis. Inflamm Bowel Dis. 2017; 23:1394–1402.
Iborra M, García-Morales N, Rubio S, Bertoletti F, Calvo M, Taxonera C, et al. Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients. Sci Rep. 2020; 10:17774.